Analytical Data
-
Gene name
HLA-B*07:02&B2M Monomer
- Application
-
Alternative Names
HLA-B*0702 & B2M
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
QDK63242.1 (G25-V309)&P61769
-
Expression Region
QDK63242.1 (G25-V309)&P61769 (I21-M119)
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-B*07:02 is a major histocompatibility complex (MHC) class I molecule that plays a crucial role in the immune response by presenting peptide antigens to CD8+ T cells. Its significance is underscored by its association with various diseases, including susceptibility to viral infections and autoimmune disorders. The β2-microglobulin (B2M) is an essential component that stabilizes the MHC class I structure and is critical for its functional expression on the cell surface. Researching the HLA-B*07:02 and B2M monomeric protein complex helps elucidate the mechanisms of antigen presentation and immune recognition. Such studies are vital for understanding the role of HLA-B*07:02 in disease predisposition, vaccine development, and immunotherapy approaches. By recombinantly producing HLA-B*07:02 and B2M, researchers can investigate the structure-function relationships of this complex, discover potential peptide ligands, and assess its interactions with T cell receptors. This knowledge contributes to advancements in personalized medicine and the design of novel therapeutic strategies targeting immune responses. Overall, the study of HLA-B*07:02 and B2M recombinantly expressed proteins offers valuable insights into the adaptive immune system's workings and its implications for health and disease.
